{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:50:33Z","timestamp":1790923833698,"version":"4.1.0"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100003135","name":"Minnesota Ovarian Cancer Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003135","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.semcancer.2019.09.021","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T12:02:06Z","timestamp":1569412926000},"page":"21-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Repurposing quinacrine for treatment-refractory cancer"],"prefix":"10.1016","volume":"68","author":[{"given":"Derek B.","family":"Oien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Pathoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upasana","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhu","family":"Thirusangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftheria","family":"Kalogera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viji","family":"Shridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2019.09.021_bib0005","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.2217\/fon.09.127","article-title":"New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents","volume":"5","author":"Gurova","year":"2009","journal-title":"Future Oncol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1478-811X-9-13","article-title":"Beyond DNA binding - a review of the potential mechanisms mediating quinacrine\u2019s therapeutic activities in parasitic infections, inflammation, and cancers","volume":"9","author":"Ehsanian","year":"2011","journal-title":"Cell Commun. Signaling: CCS"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2307\/3281795","article-title":"The chemotherapy of parasitic infections","volume":"72","author":"Campbell","year":"1986","journal-title":"J. Parasitol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0020","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.3748\/wjg.v12.i39.6366","article-title":"Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children","volume":"12","author":"Canete","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0025","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/000992288202100704","article-title":"Treatment of giardiasis: literature review and recommendations","volume":"21","author":"Lerman","year":"1982","journal-title":"Clin. Pediatr."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-3083.2006.01737.x","article-title":"The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus","volume":"63","author":"Toubi","year":"2006","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0035","first-page":"472","article-title":"Quinacrine but not chloroquine inhibits PMA induced upregulation of matrix metalloproteinases in leukocytes: quinacrine acts at the transcriptional level through a PLA2-independent mechanism","volume":"33","author":"Stuhlmeier","year":"2006","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0040","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1159\/000246899","article-title":"The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus","volume":"189","author":"Feldmann","year":"1994","journal-title":"Dermatology (Basel, Switzerland)"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0045","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/rheumatology\/36.7.799","article-title":"Antimalarial drugs in the treatment of rheumatological diseases","volume":"36","author":"Rynes","year":"1997","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0050","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/0049-0172(89)90050-4","article-title":"The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination","volume":"18","author":"Wallace","year":"1989","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0055","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0022-5223(19)39806-X","article-title":"Recurrent spontaneous pneumothorax in the high-risk patient. Management with intrapleural quinacrine","volume":"66","author":"Cattaneo","year":"1973","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0060","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/0003-4975(93)90999-X","article-title":"Intrapleural quinacrine instillation for recurrent pneumothorax or persistent air leak","volume":"55","author":"Janzing","year":"1993","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0065","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0003-4975(10)63772-1","article-title":"Intrapleural instillation of quinacrine for treatment of recurrent spontaneous pneumothorax","volume":"28","author":"Larrieu","year":"1979","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0070","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1136\/thx.48.8.790","article-title":"Chemical pleurodesis in malignant pleural effusions: a randomised prospective study of mepacrine versus bleomycin","volume":"48","author":"Koldsland","year":"1993","journal-title":"Thorax"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/bjs.1800640113","article-title":"Quinacrine in the management of malignant pleural effusion","volume":"64","author":"Taylor","year":"1977","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0080","first-page":"339","article-title":"Pleural malignancies including mesothelioma","volume":"1","author":"Hillerdal","year":"1995","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0085","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1128\/jvi.74.10.4894-4897.2000","article-title":"Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation","volume":"74","author":"Doh-Ura","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0090","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.contraception.2008.02.011","article-title":"Safety of quinacrine contraceptive pellets: results from 10-year follow-up in Vietnam","volume":"78","author":"Sokal","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0095","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0015-0282(16)57731-0","article-title":"Cancer risk among women sterilized with transcervical quinacrine hydrochloride pellets, 1977 to 1991","volume":"64","author":"Sokal","year":"1995","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0100","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0015-0282(16)57750-4","article-title":"Prevalence and standardized incidence rates of preclinical cervical pathology among 1,061 women sterilized with transcervical quinacrine hydrochloride pellets","volume":"64","author":"Dabancens","year":"1995","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF01849629","article-title":"100,000 quinacrine sterilizations","volume":"12","author":"Kessel","year":"1996","journal-title":"Adv. Contracept."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ygyno.2017.04.022","article-title":"Quinacrine in endometrial cancer: repurposing an old antimalarial drug","volume":"146","author":"Kalogera","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0115","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.21037\/tcr.2016.07.45","article-title":"TP53 mutations as a biomarker for high-grade serous ovarian cancer: are we there yet?","volume":"5","author":"Oien","year":"2016","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0120","doi-asserted-by":"crossref","first-page":"S514","DOI":"10.21037\/tcr.2016.09.32","article-title":"Regulation of chemo-sensitivity in ovarian cancer via a stroma dependent gluathione pathway","volume":"5","author":"Oien","year":"2016","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0125","first-page":"931","article-title":"Autophagy: from phenomenology to molecular understanding in less than a decade, Nature reviews","volume":"8","author":"Klionsky","year":"2007","journal-title":"Mol. Cell Biol."},{"issue":"Suppl 3","key":"10.1016\/j.semcancer.2019.09.021_bib0130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.10-90003-20","article-title":"Extending survival with chemotherapy in metastatic breast cancer","volume":"10","author":"O\u2019Shaughnessy","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0135","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/448645a","article-title":"New uses for old drugs","volume":"448","author":"Chong","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0140","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2125.2007.03058.x","article-title":"Old drugs\u2014new uses","volume":"64","author":"Aronson","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0145","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1517\/13543784.15.11.1295","article-title":"Complementary new approaches enable repositioning of failed drug candidates","volume":"15","author":"Tartaglia","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0150","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1358\/dnp.2009.22.2.1343228","article-title":"The value of drug repositioning in the current pharmaceutical market","volume":"22","author":"Tobinick","year":"2009","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge, nature reviews","volume":"9","author":"Paul","year":"2010","journal-title":"Drug Discovery"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0160","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamainternmed.2017.3601","article-title":"Research and development spending to bring a single cancer drug to market and revenues after approval","volume":"177","author":"Prasad","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0165","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fonc.2017.00273","article-title":"Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics","volume":"7","author":"Hernandez","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0170","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs, nature reviews","volume":"3","author":"Ashburn","year":"2004","journal-title":"Drug Discovery"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0175","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: new estimates of drug development costs","volume":"22","author":"DiMasi","year":"2003","journal-title":"J. Health Econ."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0180","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/clpt.2013.1","article-title":"Computational drug repositioning: from data to therapeutics","volume":"93","author":"Hurle","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0185","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cncr.27706","article-title":"Metformin intake is associated with better survival in ovarian cancer: a case-control study","volume":"119","author":"Kumar","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0190","doi-asserted-by":"crossref","DOI":"10.7326\/M17-3085","article-title":"Use of low-dose aspirin and mortality after prostate cancer diagnosis: a nationwide cohort study","author":"Skriver","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203957","article-title":"Systematic review update of observational studies further supports aspirin role in cancer treatment: time to share evidence and decision-making with patients?","volume":"13","author":"Elwood","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0200","article-title":"Strategies used by adults aged 18\u201364 to reduce their prescription drug costs, 2017","author":"Cohen","year":"2019","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0205","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.sbi.2006.01.013","article-title":"Can we rationally design promiscuous drugs?","volume":"16","author":"Hopkins","year":"2006","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0210","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2174\/157016306780368117","article-title":"Pathway analysis for design of promiscuous drugs and selective drug mixtures","volume":"3","author":"Sivachenko","year":"2006","journal-title":"Curr. Drug Discov. Technol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0215","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/bjc.1997.272","article-title":"Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine","volume":"75","author":"de Souza","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0220","doi-asserted-by":"crossref","first-page":"17448","DOI":"10.1073\/pnas.0508888102","article-title":"Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors","volume":"102","author":"Gurova","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0225","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1038\/bcj.2015.31","article-title":"Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia","volume":"5","author":"Eriksson","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0230","doi-asserted-by":"crossref","first-page":"6568","DOI":"10.1158\/1078-0432.CCR-07-1591","article-title":"Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer","volume":"13","author":"Friedman","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0235","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1535-7163.MCT-14-0013","article-title":"Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-kappaB, and cell-cycle progression in non-small cell lung cancer","volume":"13","author":"Dermawan","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0240","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0022-2836(61)80004-1","article-title":"Structural considerations in the interaction of DNA and acridines","volume":"3","author":"Lerman","year":"1961","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0245","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1073\/pnas.49.1.94","article-title":"The structure of the DNA-acridine complex","volume":"49","author":"Lerman","year":"1963","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0250","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s00216-004-2797-5","article-title":"Voltammetric studies of the interaction of quinacrine with DNA","volume":"380","author":"Aslanoglu","year":"2004","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0255","first-page":"1363","article-title":"Specific interactions between quinacrine and self-complementary deoxydinucleotides","volume":"6","author":"Doglia","year":"1986","journal-title":"Anticancer Res."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0260","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/07391102.2000.10506674","article-title":"Interaction of antimalarial drug quinacrine with nucleic acids of variable sequence studied by spectroscopic methods","volume":"18","author":"Rivas","year":"2000","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0265","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0006-3495(81)84746-7","article-title":"Fluorescence-determined preferential binding of quinacrine to DNA","volume":"36","author":"Baldini","year":"1981","journal-title":"Biophys. J."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0270","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002530","article-title":"Curaxins: anticancer compounds that simultaneously suppress NF-kappaB and activate p53 by targeting FACT","volume":"3","author":"Gasparian","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0275","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/dna.2007.0652","article-title":"DNA intercalation by quinacrine and methylene blue: a comparative binding and thermodynamic characterization study","volume":"27","author":"Hossain","year":"2008","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0280","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1073\/pnas.55.6.1511","article-title":"Reactions of quinine, chloroquine, and quinacrine with DNA and their effects on the DNA and RNA polymerase reactions","volume":"55","author":"O\u2019Brien","year":"1966","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0285","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0015-0282(00)00581-1","article-title":"Cancer risk among women sterilized with transcervical quinacrine in Chile: an update through 1996","volume":"74","author":"Sokal","year":"2000","journal-title":"Fertil. Steril."},{"issue":"Suppl 2","key":"10.1016\/j.semcancer.2019.09.021_bib0290","first-page":"S23","article-title":"25 years of quinacrine sterilization experience in Chile: review of 2,592 cases","volume":"83","author":"Zipper","year":"2003","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0295","first-page":"47","article-title":"The united states army and malaria control in world war II","volume":"42","author":"Hays","year":"2000","journal-title":"Parassitologia"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0300","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ijc.26158","article-title":"Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity","volume":"130","author":"Preet","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0305","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1039\/c2an15870a","article-title":"Recognize three different human telomeric G-quadruplex conformations by quinacrine","volume":"137","author":"Sun","year":"2012","journal-title":"Analyst"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0310","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1016\/S0960-894X(99)00394-7","article-title":"Human telomerase inhibition by substituted acridine derivatives","volume":"9","author":"Harrison","year":"1999","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0315","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2174\/138955708785909880","article-title":"Design of selective G-quadruplex ligands as potential anticancer agents","volume":"8","author":"Tan","year":"2008","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0320","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1021\/jm990287e","article-title":"Molecular modeling studies on G-quadruplex complexes of telomerase inhibitors: structure-activity relationships","volume":"42","author":"Read","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0325","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0027-5107(02)00028-3","article-title":"Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay","volume":"503","author":"Snyder","year":"2002","journal-title":"Mutat. Res."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0330","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF01226265","article-title":"Preferential inhibition of DNA polymerases alpha, delta, and epsilon from Novikoff hepatoma cells by inhibitors of cell proliferation","volume":"122","author":"Fox","year":"1996","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0335","article-title":"Quinacrine impairs enterovirus 71 RNA replication by preventing binding of polypyrimidine-tract binding protein with internal ribosome entry sites","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0340","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/271681a0","article-title":"Inhibition of hepatitis B DNA polymerase by intercalating agents","volume":"271","author":"Hirschman","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0345","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1099\/00221287-68-2-135","article-title":"Inhibition of growth and RNA biosynthesis of Bacillus cereus by quinacrine","volume":"68","author":"Seligman","year":"1971","journal-title":"J. Gen. Microbiol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0350","doi-asserted-by":"crossref","DOI":"10.3390\/cells8010055","article-title":"The ribosome biogenesis-cancer connection","volume":"8","author":"Penzo","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0355","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00130404-200405000-00001","article-title":"Cyclooxygenase-2 and gastrointestinal cancer","volume":"10","author":"Mann","year":"2004","journal-title":"Cancer J. (Sudbury, Mass.)"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0360","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.juro.2007.12.037","article-title":"The arachidonic acid pathway and its role in prostate cancer development and progression","volume":"179","author":"Patel","year":"2008","journal-title":"J. Urol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0365","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.mcp.0000166493.77412.2d","article-title":"Lung cancer: genetics of risk and advances in chemoprevention","volume":"11","author":"Keith","year":"2005","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0370","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2174\/138161207781368800","article-title":"Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option?","volume":"13","author":"Jimenez","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0375","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1365-2036.2005.02667.x","article-title":"Systematic review: the chemoprevention of oesophageal adenocarcinoma","volume":"22","author":"Mehta","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0380","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122661","article-title":"Arachidonic acid metabolite as a novel therapeutic target in breast cancer metastasis","volume":"18","author":"Borin","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0385","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/S0021-9258(19)69214-8","article-title":"Phospholipase A2 activity specific for phosphatidic acid. A possible mechanism for the production of arachidonic acid in platelets","volume":"256","author":"Billah","year":"1981","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0390","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1021\/bi00243a036","article-title":"Interfacial catalysis by phospholipase A2: dissociation constants for calcium, substrate, products, and competitive inhibitors","volume":"30","author":"Jain","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0395","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0005-2760(85)90114-6","article-title":"Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver","volume":"835","author":"Loffler","year":"1985","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0400","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1016\/S0021-9258(18)34581-2","article-title":"Direct interaction of mepacrine with erythrocyte and platelet membrane phospholipid","volume":"257","author":"Dise","year":"1982","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0405","doi-asserted-by":"crossref","first-page":"12051","DOI":"10.1021\/bi980430q","article-title":"Binding of quinacrine to acidic phospholipids and pancreatic phospholipase A2. Effects on the catalytic activity of the enzyme","volume":"37","author":"Mustonen","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0410","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/0006-291X(77)90981-0","article-title":"Quinacrine is a prostaglandin antagonist","volume":"76","author":"Horrobin","year":"1977","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0415","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0166-6851(90)90202-W","article-title":"A nuclear magnetic resonance study of the interactions of the antimalarials chloroquine, quinacrine, quinine and mefloquine with lipids extracted from normal human erythrocytes","volume":"38","author":"Zidovetzki","year":"1990","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0420","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1016\/0006-2952(83)90154-5","article-title":"Studies on the mechanism of alteration by propranolol and mepacrine of the metabolism of phosphoinositides and other glycerolipids in the rabbit iris muscle","volume":"32","author":"Abdel-Latif","year":"1983","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0425","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1042\/bj2470095","article-title":"A major role for phospholipase A2 in antigen-induced arachidonic acid release in rat mast cells","volume":"247","author":"Yamada","year":"1987","journal-title":"Biochem. J."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0430","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1677\/joe.0.1350383","article-title":"Activation of phospholipase A2 and phospholipase C by endothelin-1 in human endometrium","volume":"135","author":"Ahmed","year":"1992","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0435","first-page":"17","article-title":"Mepacrine protects the isolated rat heart during hypoxia and reoxygenation\u2014but not by inhibition of phospholipase A2","volume":"92","author":"Bugge","year":"1997","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0440","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0021-9258(19)75660-9","article-title":"The role of phospholipase A activity in rat liver microsomal lipid peroxidation","volume":"262","author":"Beckman","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0445","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0309-1651(86)90126-8","article-title":"Effects of inhibitors of arachidonic acid metabolism on intercellular adhesion of SV40-3T3 cells","volume":"10","author":"Evans","year":"1986","journal-title":"Cell Biol. Int. Rep."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0450","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1016\/0006-2952(86)90390-4","article-title":"Differential effects of mepacrine, chloroquine and hydroxychloroquine on superoxide anion generation, phospholipid methylation and arachidonic acid release by human blood monocytes","volume":"35","author":"Hurst","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0455","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0024-3205(85)90070-0","article-title":"Quinacrine antagonizes the effects of Na,K-ATPase inhibitors on renal prostaglandin E2 release but not their effects on renin secretion","volume":"36","author":"Churchill","year":"1985","journal-title":"Life Sci."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0460","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0006-2952(84)90372-1","article-title":"Prostaglandin biosynthesis in rabbit kidney: mepacrine inhibits renomedullary cyclooxygenase","volume":"33","author":"Erman","year":"1984","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0465","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1055\/s-0038-1665312","article-title":"Mepacrine blockade of arachidonate-induced washed platelet aggregation: relationship to mepacrine inhibition of platelet cyclooxygenase","volume":"50","author":"Raz","year":"1983","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0470","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0003-9861(82)90300-9","article-title":"The effects of mepacrine and p-bromophenacyl bromide on arachidonic acid release in human platelets","volume":"215","author":"Hofmann","year":"1982","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0475","first-page":"307","article-title":"Comparison of the effects of chloroquine quinacrine and quinidine on autonomic neuroeffector mechanisms","volume":"60","author":"Lot","year":"1982","journal-title":"Med. Biol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0480","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.2042-7158.1982.tb06212.x","article-title":"Stimulation of polymorphonuclear leucocyte phospholipase A2 activity by chloroquine and mepacrine","volume":"34","author":"Authi","year":"1982","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0485","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0090-6980(87)90013-X","article-title":"Inhibition of complement-mediated hepatic thromboxane production by mepacrine, a phospholipase inhibitor","volume":"33","author":"Flynn","year":"1987","journal-title":"Prostaglandins"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0490","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1111\/j.1349-7006.2009.01258.x","article-title":"Prostaglandin E2, Wnt, and BMP in gastric tumor mouse models","volume":"100","author":"Oshima","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0495","doi-asserted-by":"crossref","first-page":"19396","DOI":"10.1074\/jbc.M213290200","article-title":"Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis","volume":"278","author":"Kamei","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0500","first-page":"3971","article-title":"Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer","volume":"7","author":"Yoshimatsu","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0505","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1472-8206.2008.00613.x","article-title":"Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine","volume":"22","author":"Liang","year":"2008","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0510","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0167-4889(89)90239-5","article-title":"Increased cellular internalization of amphiphiles in a multidrug-resistant CHO cell line","volume":"1014","author":"Boscoboinik","year":"1989","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0515","first-page":"2064","article-title":"Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine","volume":"48","author":"Inaba","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0520","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0006-291X(88)81321-4","article-title":"Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine","volume":"153","author":"Beck","year":"1988","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0525","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.4049\/jimmunol.161.7.3421","article-title":"Selective inhibitors of cytosolic or secretory phospholipase A2 block TNF-induced activation of transcription factor nuclear factor-kappa B and expression of ICAM-1","volume":"161","author":"Thommesen","year":"1998","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0530","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122603","article-title":"Quinacrine inhibits ICAM-1 transcription by blocking DNA binding of the NF-kappaB subunit p65 and sensitizes human lung adenocarcinoma A549 cells to TNF-alpha and the fas ligand","volume":"18","author":"Harada","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0535","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1126\/science.1085703","article-title":"FACT facilitates transcription-dependent nucleosome alteration","volume":"301","author":"Belotserkovskaya","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0540","doi-asserted-by":"crossref","first-page":"23297","DOI":"10.1074\/jbc.R600007200","article-title":"De FACTo nucleosome dynamics","volume":"281","author":"Reinberg","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0545","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0092-8674(00)80903-4","article-title":"FACT, a factor that facilitates transcript elongation through nucleosomes","volume":"92","author":"Orphanides","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0550","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav2131","article-title":"Mechanism of FACT removal from transcribed genes by anticancer drugs curaxins","volume":"4","author":"Chang","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0555","doi-asserted-by":"crossref","first-page":"8710","DOI":"10.1128\/MCB.01129-06","article-title":"A gene-specific requirement for FACT during transcription is related to the chromatin organization of the transcribed region","volume":"26","author":"Jimeno-Gonzalez","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0560","first-page":"763","article-title":"Histone chaperone FACT regulates homologous recombination by chromatin remodeling through interaction with RNF20","volume":"127","author":"Oliveira","year":"2014","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0565","doi-asserted-by":"crossref","first-page":"25736","DOI":"10.1074\/jbc.M101208200","article-title":"Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin","volume":"276","author":"Yarnell","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0570","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.molcel.2018.09.010","article-title":"The histone chaperone FACT coordinates H2A.X-Dependent signaling and repair of DNA damage","volume":"72","author":"Piquet","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0575","doi-asserted-by":"crossref","first-page":"50206","DOI":"10.1074\/jbc.M209820200","article-title":"p53 serine 392 phosphorylation increases after UV through induction of the assembly of the CK2.hSPT16.SSRP1 complex","volume":"277","author":"Keller","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0580","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1016\/j.celrep.2016.08.070","article-title":"The histone chaperone FACT contributes to DNA replication-coupled nucleosome assembly","volume":"16","author":"Yang","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0585","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.molcel.2008.02.029","article-title":"FACT-mediated exchange of histone variant H2AX regulated by phosphorylation of H2AX and ADP-ribosylation of Spt16","volume":"30","author":"Heo","year":"2008","journal-title":"Mol. Cell"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0590","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006221","article-title":"FACT assists base excision repair by boosting the remodeling activity of RSC","volume":"12","author":"Charles Richard","year":"2016","journal-title":"PLoS Genet."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0595","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev.biophys.27.1.105","article-title":"Minor groove-binding architectural proteins: structure, function, and DNA recognition","volume":"27","author":"Bewley","year":"1998","journal-title":"Annu. Rev. Biophys. Biomol. Struct."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0600","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1006\/excr.1997.3742","article-title":"The high-mobility group protein T160 binds to both linear and cruciform DNA and mediates DNA bending as determined by ring closure","volume":"236","author":"Gariglio","year":"1997","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0605","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/nar\/21.7.1643","article-title":"Isolation and characterization of cDNA clones encoding the Drosophila homolog of the HMG-box SSRP family that recognizes specific DNA structures","volume":"21","author":"Bruhn","year":"1993","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0610","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/0008-5472.CAN-17-2690","article-title":"Role of chromatin damage and chromatin trapping of FACT in mediating the anticancer cytotoxicity of DNA-Binding small-molecule drugs","volume":"78","author":"Nesher","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0615","first-page":"1925","article-title":"FACT is a sensor of DNA torsional stress in eukaryotic cells","volume":"45","author":"Safina","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0620","doi-asserted-by":"crossref","first-page":"783","DOI":"10.18632\/oncotarget.340","article-title":"Expression of FACT in mammalian tissues suggests its role in maintaining of undifferentiated state of cells","volume":"2","author":"Garcia","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0625","doi-asserted-by":"crossref","first-page":"17494","DOI":"10.1073\/pnas.0708572104","article-title":"Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays","volume":"104","author":"Hudson","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0630","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1158\/1940-6207.CAPR-11-0529","article-title":"Targeting FACT complex suppresses mammary tumorigenesis in Her2\/neu transgenic mice","volume":"5","author":"Koman","year":"2012","journal-title":"Cancer Prev. Res. Phila. (Phila. Pa)"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0635","doi-asserted-by":"crossref","first-page":"20525","DOI":"10.18632\/oncotarget.15656","article-title":"Level of FACT defines the transcriptional landscape and aggressive phenotype of breast cancer cells","volume":"8","author":"Fleyshman","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0640","first-page":"301","article-title":"Prognostic value of histone chaperone FACT subunits expression in breast cancer","volume":"9","author":"Attwood","year":"2017","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0645","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fphar.2013.00068","article-title":"Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy","volume":"4","author":"Crawford","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0650","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: strategies for overcoming resistance to chemotherapy","volume":"3","author":"Agarwal","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0655","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fonc.2013.00251","article-title":"Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment","volume":"3","author":"Chien","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0660","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3389\/fphar.2017.00970","article-title":"Cisplatin and pemetrexed activate AXL and AXL inhibitor BGB324 enhances mesothelioma cell death from chemotherapy","volume":"8","author":"Oien","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0665","article-title":"Genetic regulation of longevity and age-associated diseases through the methionine sulfoxide reductase system","author":"Oien","year":"2018","journal-title":"Biochimica et biophysica acta. Molecular basis of disease"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0670","doi-asserted-by":"crossref","first-page":"36354","DOI":"10.18632\/oncotarget.5632","article-title":"Quinacrine promotes autophagic cell death and chemosensitivity in ovarian cancer and attenuates tumor growth","volume":"6","author":"Khurana","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0675","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1038\/s41598-018-20531-w","article-title":"Quinacrine upregulates p21\/p27 independent of p53 through autophagy-mediated downregulation of p62-Skp2 axis in ovarian cancer","volume":"8","author":"Jung","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0680","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bcp.2016.01.017","article-title":"Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade","volume":"105","author":"Preet","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0685","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.dnarep.2016.05.034","article-title":"ABT-888 and quinacrine induced apoptosis in metastatic breast cancer stem cells by inhibiting base excision repair via adenomatous polyposis coli","volume":"45","author":"Siddharth","year":"2016","journal-title":"DNA Repair"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0690","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s13402-017-0347-3","article-title":"TRAIL enhances quinacrine-mediated apoptosis in breast cancer cells through induction of autophagy via modulation of p21 and DR5 interactions","volume":"40","author":"Das","year":"2017","journal-title":"Cell. Oncol. (Dordr)"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0695","doi-asserted-by":"crossref","first-page":"248","DOI":"10.18632\/oncotarget.11335","article-title":"Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade","volume":"8","author":"Das","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0700","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3727\/096504012X13473664562628","article-title":"Quinacrine-mediated autophagy and apoptosis in colon cancer cells is through a p53- and p21-dependent mechanism","volume":"20","author":"Mohapatra","year":"2012","journal-title":"Oncol. Res."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0705","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/1541-7786.MCR-17-0511","article-title":"Therapeutic effect of quinacrine, an antiprotozoan drug, by selective suppression of p-CHK1\/2 in p53-Negative malignant cancers","volume":"16","author":"Park","year":"2018","journal-title":"Mol. Cancer Res. MCR"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0710","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/carcin\/bgs351","article-title":"Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC","volume":"34","author":"Preet","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0715","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4161\/cbt.12.3.17033","article-title":"Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents","volume":"12","author":"Wang","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0720","doi-asserted-by":"crossref","first-page":"19162","DOI":"10.1074\/jbc.M109.091645","article-title":"Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin","volume":"285","author":"Jani","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0725","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.2217\/fon-2017-0728","article-title":"Novel applications for an established antimalarial drug: tumoricidal activity of quinacrine","volume":"14","author":"Yan","year":"2018","journal-title":"Future Oncol. (Lond., Engl.)"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0730","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/cr.2011.152","article-title":"Autophagy: for better or for worse","volume":"22","author":"Wirawan","year":"2012","journal-title":"Cell Res."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0735","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1208\/s12248-018-0254-1","article-title":"Emerging cancer Therapeutic targets in protein homeostasis","volume":"20","author":"Bastola","year":"2018","journal-title":"AAPS J."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0740","first-page":"362","article-title":"Autophagy regulation in cancer development and therapy","volume":"1","author":"White","year":"2011","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0745","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1757-2215-5-22","article-title":"Involvement of autophagy in ovarian cancer: a working hypothesis","volume":"5","author":"Peracchio","year":"2012","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0750","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1158\/1535-7163.MCT-05-0102","article-title":"Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells","volume":"4","author":"Safaei","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0755","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.ejca.2011.01.019","article-title":"p62\/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins","volume":"47","author":"Yu","year":"2011","journal-title":"Eur. J. Cancer (Oxf. Engl. 1990)"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0760","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1091\/mbc.e08-07-0671","article-title":"The TP53INP2 protein is required for autophagy in mammalian cells","volume":"20","author":"Nowak","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0765","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/462658","article-title":"Expression and clinical significance of the autophagy proteins BECLIN 1 and LC3 in ovarian cancer","volume":"2014","author":"Valente","year":"2014","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0770","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0775","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000313525","article-title":"Quinacrine enhances cisplatin-induced cytotoxicity in four cancer cell lines","volume":"56","author":"Wang","year":"2010","journal-title":"Chemotherapy"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0780","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41419-018-0679-6","article-title":"Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition","volume":"9","author":"Jing","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0785","first-page":"1673","article-title":"Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma","volume":"15","author":"Lobo","year":"2013","journal-title":"Neurooncology"},{"key":"10.1016\/j.semcancer.2019.09.021_bib0790","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.leukres.2017.10.012","article-title":"Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects","volume":"63","author":"Eriksson","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2019.09.021_bib0795","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10637-017-0515-3","article-title":"Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer","volume":"36","author":"Bhateja","year":"2018","journal-title":"Invest. New Drugs"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X19302263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X19302263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:47:11Z","timestamp":1760917631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X19302263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":159,"alternative-id":["S1044579X19302263"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2019.09.021","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing quinacrine for treatment-refractory cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2019.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}